The Multiple Myeloma Research Foundation announced late last week its multi-year collaboration with Millennium Pharmaceuticals: The Takeda Oncology company. Both parties are interested in pursuing effective and curative treatments for myeloma, both parties also believe that a more personalized approach is necessary in order to advance treatment.
“Millennium is committed to advancing the field of personalized medicine to bring treatments to patients who can benefit from them the most,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “We believe strongly that the MMRF’s Personalized Medicine Initiative will greatly improve our basic understanding of multiple myeloma, and will transform the way the entire research community works to turn new insights into testable hypotheses, and hypotheses into new treatments. We are proud to be the first company to support this critically important work.”
The MMRF recently launched a massive study called The CoMMpass Study which will collect and analyze tissue samples and genetic information from approximately 1,000 multiple myeloma patients over the next 5 years. When MMRF announced this, we were one of the first blogs to help spread the news. Here is what Kathi Giusti, co-founder and director of the MMRF said about the recent partnership with Millennium:
“For more than a decade, Millennium has been a true and strong ally for the MMRF and patients affected by multiple myeloma, and we are delighted for the pioneering support of the Personalized Medicine Initiative,” said Kathy Giusti, Founder and CEO of the MMRF and Multiple Myeloma Research Consortium, and a multiple myeloma patient. “The MMRF and Millennium share a common vision for the future—to greatly improve our understanding of the patient-by-patient variability for multiple myeloma as a means of informing the development of new treatments, and ultimately, cures.” [1]
Both the MMRF and Millennium are dedicated to curing multiple myeloma. This partnership bodes well for the multiple myeloma community, and may one day set a precedent for how pharmaceutical companies and nonprofit groups can work together — united, for the cure.
To learn more about the CoMMpass study click here.
Related posts:
- MMRF’s CoMMpass Clinical Trial Aimed at Assessing Myeloma Outcomes and Genetic Profiles Enrolls First Patient
- The Multiple Myeloma Research Foundation and Onyx Pharmaceuticals – Dedicated to better treatments for Multiple Myeloma
- Looking for Multiple Myeloma Clinical Trials? Head over to the MMRF!
- MMRF’s Clinical Insights In Multiple Myeloma: Learn more
- Aptuit, Paytheon Pounding Miles in the ING NYC 2010 Marathon for the MMRF